. >> celgene multiples closer to 20. >> you know what? i'm going to revise everything right here right now. >> okay. >> the other one to watch, what is the drug company that has the most momentum, that is loved the most in the country, that is revered, thought to be like perhaps the greatest narrative of all time the $25 -- >> actavis. i got it. >> how do you -- you why a "jeopardy!" champion. >> i got it. i was nervous. so that's -- >> make it happen. >> around 300. >> if actavis turns around and celgene turn around, it's going to be a bit of a nice day. >> let's talk mcdonald's for a second. easterbrook is here somewhere, at the nyc. i believe an investor meeting today. >> double cheese burger? >> i would assume. >> everybody has to have one. i went to phillipip morris there was a pack of marlboro lights

celgene to me continues to go higher. don't trade apple. same thing with celgene.'t trade it. >> are you in biogen? >> pete is but, again, this is phase 1, right? tomorrow with biogen. that's phase one with them about the monochromal antibody. the pe is up there in the stratos fear versus biogwen. >>> tesla coe elon musk says hands free is own a few months away. so why did the stock sell off after the big vote of confidence? a deeper dive into what's behind that move. that's next. yes, when others focus on one thing, you see what's coming next. you see opportunity. that's what a type e does. and so it begins. with e*trade's investing insights center, you can spot trends before they become trendy. e*trade. opportunity is everywhere. >>> "fast money" live from the nasdaq. tesla has anxiety and is giving some investors anxiety about the stock. we have an analyst that says you should buy everything you can. >>> nike shares moving higher. a conference call about halfway through. the latest from the ceo. facebook, google and apple making payment sexy again. originals. eb

biogen, celgene, gilead. these are the top holdings. >> biotechs in a bubble, a lot of these companies have no earnings, which i get a. lot are biotech in name only. celgene, gilead, amgen, looking at how pristine the balance is, no debt. i don't think those are necessarily in. i think cellgene continues to hire. gilead, amgen. that's a real story we talked about. >> if you seen this news, celgene announced in the new england journal, it's gaining acceptance. that's to me often been time to fade somebody. few look at the ibb, the rsi, the relative strength indicator, momentum. everything jeffrey was saying. are you in a third place where we are trading 81, 82, 83, which is way overbought territory. it's pulled back every single time. they have been pullbacks to buy. jumping in on monday to buy these stocks after huge runs, i think you have to be cautious. >> i spoke about this a lot. when you go with the ibb, you go with the top holdings on it. look at my clearance, clo vis pharmaceuticals down 52%. this year

we're going to hang out. >> guy, if you had to buy one pullback today. >> celgene. in the biotech space, celgene to me is -- i shouldn't say this but i think it's a bulletproof company. yeah. >> all right. >> out on a limb. >> source in sell-off number two in what is hitting much of the broader market, oil rallying 3% while the transports took a hit. a lot of people pointing to the transports as not confirming the most recent highs made on the s&p 500, that is if you are a dow theorist. are you? >> i'll tell you what, there are certain times in the market cycle and the economic cycle that makes a ton of sense. i think we're in a place where late cyclicals work. i think transports to me have a function of two things. they've mad major, major moves, highly sensitive to oil and gas movements. i think we're in a place where market rotation and lack of confidence also with the fed leaves all these guys vulnerable to dollar moves. the interesting thing is the dollar remains sideways to downwards today. again, you can't look at them all the same. if you look to me the rail

. >> celgene. >> really? >> everything's terrific with celgene. that stock's been going down.eason that's important, it's not a fly by night biotech it's a biotech with good earning stream. if that doesn't stop you're going to be in trouble because biotech's the leadership group. >> shouldn't it cause at least refreshment, 70 to 130 in less than a year. >> you asked for the key to the market, david. that's the delta, that's the marginal one that you asked me for. you didn't ask me for bristol-myers. >> no, i didn't. i got my answer. there is the opening bell. back to the real-time exchange headquarters. here at the big board, franklin financial networks celebrates its initial public offering today. and over at the nasdaq solar edge technologies also celebrating an ipo. two ipos. >> very strong first solar strong, the idea they can spin off a business has a yield co. >> yes. >> you think with oil down the stock would be decimated but they're not. the overall drive, this is for conservation, it doesn't matter where oil is. that group is not as weak as you would think. some say t

celgene saw above average call volume.thank morning, someone bought 2600 of the march 1 24 calls for 50 cents and bought 2800 of the 125 calls that expire a week later for about 70 cents. this is a name that is going to be presenting at the barclays capital health conference on wednesday. and that might be the catalyst they're targeting as they approach a bullish trade on the stock, thinking the stock might be up over 6% in just over two weeks. >> all right. thanks for that, mike. for more "options action" check out the live show 5:30 eastern time on fridays. let's get to a tweet. >> oh, my gosh. >> we love getting them. we love answering them here is the first tweet. this is for guy. also in biotech. amgen, buy or hold? >> it's the same thing karen will told you. >> or sell. throw a sell in there. >> throw a buy in there. >> all right. >> 15 times forward earnings makes the stock cheap when you compare to it major biotext and major pharma stocks. it has a tremendous pipeline, a tremendous amount of drugs out there already

i think celgene is best in breed. i think gilead goes north of 110. >> and you near the xbi.more of the smaller biotechs, doesn't it? >> the big beer cap one, the smaller cap one and the mid cap one. but there's a fair amount of overlap. but i can't stomach waking up and seeing some failed trial and having the stock down huge. so it's diversified. it helps me sleep much better at night. i really believe that consolidation in the industry will continue. so one in the basket. >> perfect segue to the next guest. take a look at this move in biotech. the company spark therapeutics. doubling on the day of the ipo in late january. now up more than 220%. spark involved in the creation of gene therapies and is currently working on treatments for blindness and other genetic diseases. joining us now in a cnbc exclusive is spark's ceo, jeff marrazzo and we brought along meg terrell. all years. >> thank you. so we were just talk about companies that have to sales and $2 billion market caps and you're $1.8 billion, no sales yet. let's get to valuations in a bit, but i want to start by what

look at the biggest constituent of the biotech index, for example, what you will find are names like celgenegilead, biogen, which he mentioned. these are vaims names seeing double digit top line growth and we're not trading at ludicrous multiples a year ago. the others were up 60-70% off their one-year lows. >> that issue gets them to the same place the s&p is. which is while they were once cheap, they were pretty much fully valued if you look at their multiple to growth. i'm kind of in this camp with carter here, thinking it's a good story, in most cases, it makes it tough the trade here. >> what's the trade here? >> i think we're looking for an opportunity for a put spread. because biotechs tends to be more volatile in some instances, you can finance the puts. specifically i'm looking at the june 16th put. sell the 320s for 5-and-a-half dollars in this instance, you are spending just over ten bucks or that magic ratio with these put spreads about 25% of the distance to make a bearish bet here. >> i was talking to a couple analysts and their concern is that now we've got all these generalis

merck is not amgen, merck is not celgene, located next to each other.- it should be st. merck. we always thought of merck as the gold standard. i think merck could be making a comeback. they obviously think, they're buying back tock. but it's been a total dog. >> it has been. >> yeah, moved up but -- >> everybody believes the best opportunity for use some of their cash is buying back stock. >> we don't want tuna with good taste. we want good-tasting tuna. give us the alzheimer's drug we thought we'd get. give us something from the schering-plough deal we thought we'd get. we need results. re we need results. >> opening bell after this. hey, girl. is it crazy that your soccer trophy is talking to you right now? it kinda is. it's as crazy as you not rolling over your old 401k. cue the horns... just harness the confidence it took you to win me and call td ameritrade's rollover consultants. they'll help with the hassle by guiding you through the whole process step by step. and they'll even call your old provider. it's easy. even she could do it. whatever, j

i said celgene, biogen those are the four horsemen of the big pharma apocalypse.ou cell, cell, cell. these have gone up let's say almost in a straight line. and that's the caveat i want you to focus on. almost. when they do have their downturns, and they do, they are severe and ugly and you really don't want to buy them before those downturns. it's like yesterday. i wrote on twitter at jam cramer that everyone who complained about my recommendation of isis pharmaceutical are saying they paid the top price because it did slip down after that. listen to me, you're now up on your position. it hit an all-time high today. you're free to sell. if only so you don't blame me for any losses that you might incur. i tire of being accused of getting it wrong when thankfully, i really got this right. and i'm telling you, i don't want you to be greedy. look, i know these stocks if can still go higher and many will but i also don't want to hear, you cut me out of the next 100 points in biogen. but can i just stress, don't you think the easy -- can't you agree with me? don't you

gilead amgen, celgene, and biogen. biogen 4.5%. the smaller ones are really really harder hit. them all down almost double digits. the rest above 10%. clearly a lot of pain going on. it's been a tough week for biee tech biotech in general. it's been a losing streak for three weeks. it's causing a lot of jitters about whether the biotech run up 280% in the last five years could be ending. a lot of disagreements about that, but clearly a lot of fears today. back to you guys. >> all right, meg, thank you very much. let's talk more about this sell-off in biotech specifically right now. >> joining us now is les and barbara ryan. barbara, do you look at this space and sense opportunity or is it still looking pretty risky? >> i mean, i think you have to look at this selectively. i think meg pointed out the great performance of the sector and i think it's important to note that this is really being driven by fundamentals. number one, strong topline, bottom line growth. a lot of capital going into the space. by the same token, everything has gone up in the sector and i think investors a

among the upside standouts shares of cerner abbvie celgene, up around 1.5% to 3%.tor overall but specifically the large cap biotechs. >> thank you very much. >>> speaking of fed fireworks over to chicago, cme group. rick santelli with the santelli exchange this morning. hi, rick. >> good morning. i like to welcome my special guest, first time guest david ader. thanks for taking the time. >> thank you for having me. listen, i want to talk about greece. but not as in the country ee. i want to talk about grease the kind that makes gears move smoothly. let's rise above the issues have a macro conversation. the amount of debt out there keeps growing but yet the amount that's tradeable keeps shrinking. the type of clt ral high credit like bunds, shots, treasuries, is hunkered down whether central banks balance sheets, insurance companies, are we going to have a lot more kind of october 15th crash type markets because of this issue in your opinion? >> i think that was a dress rehearsal for what's coming. the dealer community, the cushion against sell-offs or the need for

celgene has to be up for three days before i recommend these guys.ny in pennsylvania. >> caller: hey, jim. boo-yah from philadelphia. >> yeah man! good to have you on the show. >> caller: i was looking through my portfolio and noticed a gap. i have nothing in hospitality. is that something to invest in? specifically what about hyatt? >> no, no. if you go hotels go to marriott. they are putting up great numbers. skip hyatt. alu in illinois. >> caller: professor cramer! good evening. >> good evening. >> caller: okay. so my ticker symbol is kerx. >> renal cell therapy is too speculative. not as hot as others we have had. i can't -- kerx can't stabilize until we have the big guys stabilizing. we are only in day one with of zablzation. jake in ohio. jake. >> caller: big boo-yah from cincinnati. >> wow cincinnati. don't get many calls from cincinnati. >> caller: just want you to know, a lot of respect for you. the only man willing to go on tv and give his opinion on any stock at any time. >> i am the only guy who does that. thank you for noticing. it's not

index up 240% since 2012 and the biggest names, gill he ad, up 40%, amgen up 40%, biogen up 47%, celgenep 75%. >> you can understand why the stiefel analyst on monday when we talked about this on the show why there was hesitation and pause and came down to a hold position on biogen. when you look at some of these names they have taken off. it's been an incredible run. you could have said the same thing three years ago, wow, this thing is in a bubble, last year, these things have been moving to the upside when you look at a lot of these names. the moves have been extremely sharp. a pause maybe a bit of a rotation, but to josh's point i don't necessarily think that biotechs are going to be the bubble that bursts the market. i think it's a rotational market right now and we're starting to see more and more of it come out of the bioteches into other areas. >> unless, you know, selling begets selling. steve, you play a lot in this space. >> yeah. i'm definitely involved in the space. look, i'm conflicted a about it personally because i think if you point out gilead, for example, that's a chea

when we talk biotech and we do a lot on this show there's the big-cap biotechs, the celgenes and other biotechs in the world, they have big caps and trade like big phrma names. going back to the bubble of 2000, these are the types of names that you talk about where there's great potential and now all of a sudden there's a little bit of an issue obviously. they are disturbed about what was released. it was done before it was supposed to be done and obviously that's a bit of an issue, but if there's benefits along with it as well. >> pretty amazing. >> could be pretty amazing for them as well. >> speaking of biotech and big phrma, a big move in pharmacyclics. >> we got a 2.5% on top of the move in the regular session here on reports from the "financial times" that johnson & johnson is close to buying the company pharmacyclics to a 17.5% current valuation and could be agreed upon in the coming days. remember that the company has been doing well over the past week because bloomberg did report that both johns johnson & johnson and novartis were interested in buying pharmacyclics which would

and then take a look we talk about the biotechs all the time, but big cap biotechs the move on a celgene gill he adand amgen. all participating. not just the hospital stocks. nice move to the upside. i think there's plenty of upside. >> the smaller and mid cap biotechs that people continue to believe could be in a bubble? >> they're probably right on those, though, scott. people talk about bubbles in biotech you have to just look at it and say you can't make it about everything in biotech. >> i say small -- >> smaller one specifically. at the same time, those are the most exciting ones, most volatile, you want to trade. we talked about zio pharma not that long ago. the move that has made in the last week and a half or so. look at the volumes in some names as they get close to getting drugs to the market or potentially in front of the fda. you can see some of the dramatic moves you can get as well. >> joe? >> a premium being paid for growth and growth is found in the health care industry and not surprisingly enough and i don't know if the news sticks or doesn't stick but there was always

celgene -- this green is going on to earnings till may.call for about $10 it is a cheap way to buy exposure. biotech has beaten every other sector in the s&p 500 for the last 4 years. scarlet: why not i outright -- buy it outright? >> people want to be careful and partial gains. you can take a nominal amount and get wide returns. with the volatility and uncertainty, it is a great way to play. scarlet: there is a link to the bigger macro picture, if interest rates head higher, what does that mean for the biotech companies? >> biotech's interest rate insensitive. you can see the growth we talked about before, earnings doubled by 2020. they are not impacted by interest rates. scarlet: the jobs report is on friday, the stock market is closed, you will be working what are you looking for? >> wage growth that is what everybody is focused on, it has been lagging. we are seeing wages rise and lower. scarlet: we will be back. ♪ pimm: welcome to money clip. i am pimm fox. around the world syrian president bashar al-assad is still in power. he says h

big drug celgene cancer product. vertex and gilead high profile hepatitis c treatment, is a valued y savaldi. big names in performers. >> hot sector. dom, thank you. >>> brian sullivan counting russian. >> one two three -- here you go. according to baker hughes tyler, down 41 rigs from last week. interesting for a couple of reasons. one, it's a lowest number of drilling rigs out there. only talking oil now. lost 15 gas. that is the lowest number of oil rigs since march of 2011. what is also interesting is we were down 56 drills rigs from last week. so while we declined another 41 in oil, the rate of deck clination, rigs pulled off slowed down the first time in a while. 41 lost last week. 56 the previous week. price of crude oil looking here up a nickel. not seeing much of a reaction there, guys. canada crushed again, but a lot of weather stuff going on in canada. it's cold people aren't moving rig, whatever. lost 80 rigs last week. canada has lost almost half its drilling rigsdown 41 in the united states. lowest sinc

i should say the worst performers are invidea, biogen vertex pharma and celgene.orst performers this week. they're down 9% 8% 7% respectively. now time for street talk. let's find some opportunities. hitting five stocks with news or analyst recommendations just for you. let's get to it. >> let's do it. >> stock one, harley davidson. stifel, starting coverage with a buy. they have a $75 coverage. 25% up side. they like the product invasion. they have the dart custom platform, et cetera as well as the potential for dividend and buyback opportunities. they called a valuation reasonable. >> i think they're even looking into a hog, brian. take a look at the stock chart. it's fallen and been treading water. it will be interesting to see if the good performance on the down day overall. stock number two here tesla. underperform from an outperform. cutting the price target to 220 from 275. the loits sees risks to the near term earnings from a lower model x margin. we've heard this from other analysts before. longer term though the analyst says the stock is attractive and d

biotech is a bottom because of the celgene, biogen going higher. talk about semis.utions that had been along with nxpi avago and corvo, the four, they're coming back. in other words, two groups that let us down bottomed now coming back i don't believe there's a bubble in biotech. i think some stocks got overheated. i don't think it's bubbling in semis. >> coming down you can barely see coming down. that's done nothing but gone up. >> 90 i regard that as being ai hit. if you own it you hate me. >> 158% gain over the year. >> they're in every single cell phone company, five bucks with content in iphone. >> you're a believer. >> i'm a believer. i wouldn't leave that in i tried. >> "mad" tonight? >> i'm doing analysis of what's going to happen with the strant and retail group because i've reviewed every single one. i have a new name i'm going to crown the king of a whole new group of retail. so you're going to want to stay tuned. >> that was the monkeyes. >> thank you. remember michael nateismith invented whiteout. >> he's coming back with andrew liveris. >> what am i t

you're seeing all-time highs for the likes of regeneron and celgene as well.e to be the big momentum drivers with lots of hope for their pipelines. seeing overall the large caps doing fairly well today. apple is higher. that's helping the dow as well now. all-time highs and extended gains for starbucks, also for sky works and urban outfitters but it's not the big caps that have been driving it. the nasdaq itself back to the 5,000 level the nationsdaq around 4460. its all-time high 4704 all-time high close. what's been driving this has been the small caps with the russell 2000 as well opening at a new high today. all of those bioteches in the small cap intech helping to drive things higher. amazon today getting a lift. and being allowed to test drive drone delivery. i don't know if i'm ready for that guys. i can deal with one-hour delivery by bicycle. but i don't know a drone seems like a little much. >> not sure we have a choice but we'll watch it anyway. >> rural. >> it is rural, for the time being. rick santelli in the bond pits in chicago. rick? >> hi carl.

some of the big caps in fact are the ones that are attracting names, celgene is now positive.y are providing lift. apple today has been bucking the trend. it's been up pretty much since the open and it's off its highs now, but that's really what helped to keep the dow and the big caps afloat as much as they have, and interestingly today, some of the little guys and the social media stocks today are all getting quite a bit of love. gopro upgrade over at baird. twitter raising a a development finishing up the conference. have you tried it yet? someone was petting their dog, watch cat and dog videos live live streaming. >> live streaming cat videos just what i need in my home. bertha, thank you very much. going to london folks, why not? we are live. >> hey, tyler, absolutely. renewed signs of life in the euro hitting a two week high against the dollar coming up a bit in the last two hours. what's behind the strength? well better than expected data out of the euro zone manufacturing at a four year high, and the index measuring business activity in germany surprised to be up. at th

shares of celgene and alexion lower. perrigo lower as well.r of the year in 2015 up 5% year to date. back over to you. >> that's help for for the nasdaq as well. the morning after the nasdaq closed above 5000 all eyes on penalty, one-tenth of the index. tech watchers believe apple's entry-level watch could cost $350 but one analyst thinks consumers will end up paying more than that. piper jaffray's gene munster out with a new note everyone's talking about the average sales price of the apple watch joins us now. i have to ask you, here at the nasdaq watching the 5000 level, everyone and their mother says we're not in 2000 but does the index look expensive especially as you look at how much is comprised of apple? >> if you look in cot conntext, the earnings power are very different. back in 2000 on the hope of the internet and the substance of the companies is more real. so i feel like you know, most basic level, if the companies have opportunity to grow and i think apple has a golden tune to continue eye growth rate i think it's not expenseivee

celgene is seeing sales double by 2020. janet yellen said they were overvalued.you think the market is overvalued and nasdaq is overvalued, there is an etf where you can capture that volatility. it sells options against it on a monthly basis and spitz it out to shareholders. 10.4% yield last year alone. >> is it yours? >> yeah it is. we actually issued it. if you think things are getting toppy, you can get -- >> the qyld? >> qyld. >> what lessons have you learned from the dotcom period and its aftermath? >> it's been 15 years, which is pretty incredible. you know i think people have to understand that that whole boom period was really the dawn of the internet as we know it today, and people realize how pervasive and how revolutionary it really was. not only from a consumer personal basis but also for businesses. so what spawned from that period were a lot of companies that actually are lasting and doing well today. i do think a lot of the overheated speculation is happening on the private side. a lot of these companies are waiting as long as possible before going

but the names we talk about, the celgenes amgens gileads, they're real companies so say they are in a gets back to the point that art cashin was making where we just asked him where he was seeing some interest. today he said biotech. that's maybe a place to look. ironically look for leadership again in the second quarter. >> michael. >> biotech is way too rich for my blood. we're talking about p/e ratios in the 300s. guy says what do we want him to say. here it is. you're the short-term guy. you're the "fast money" guy. so where is the market headed? is it going to go higher next quarter or not? >> let's not talk about quarters. let's talk about the here and now. we have a weird event. >> quarters do matter. >> quarter for me. it's 15 minutes from now i don't know what i'm doing. so quarter nor me is outrageous. but this friday we're going to have news come out no markets open. that doesn't happen that often. only a handful times over the last 30 years, number one. in terms of where the market is going, i just look at certain things. as long as the russell, the iwm stays above 121, an

. >> this is the celgene story.ed edd edd edd edd hemotological. but into solid tumors then the upside in hind sooigt you'll say this was a cheap acquisition. i find it interesting that j & j walked. j & j has a very rigid discipline. i remember when they crossed the scientific data and hurt boston scientific. >> all right jason. thanks. we'll talk off camera. you can hear the music. thank you. >> okay. >>> when we come back this morning, the jobs report just over 30 minutes away. our panel of experts are ready with predictions and reactions. "squawk box" will be right back. at ally bank no branches equals great rates. it's a fact. kind of like mute buttons equal danger. ...that sound good? not being on this phone call sounds good. it's not muted. was that you jason? it was geoffrey! it was jason. it could've been brenda. ♪ at mfs, we believe in the power of active management. every day, our teams collaborate around the world to actively uncover, discuss and debate investment opportunities. which leads to better dec